Lake Street Advisors Group LLC Sells 140 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lake Street Advisors Group LLC lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,199 shares of the company’s stock after selling 140 shares during the quarter. Lake Street Advisors Group LLC’s holdings in IDEXX Laboratories were worth $496,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in IDXX. Chicago Partners Investment Group LLC lifted its position in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after buying an additional 96 shares in the last quarter. National Pension Service lifted its position in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after purchasing an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC grew its stake in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after purchasing an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC raised its position in IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after purchasing an additional 2,801 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on IDXX. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Down 3.7 %

Shares of NASDAQ:IDXX opened at $441.03 on Friday. The company has a 50 day moving average price of $434.82 and a two-hundred day moving average price of $451.84. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market capitalization of $35.87 billion, a PE ratio of 41.33, a PEG ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.